Insight

Tejas Patil: First patient with mNSCLC with an EGFR-ERBB4 gene fusion who clinically and radiographically responded to EGFR TKIs

Tejas Patil/X

Dec 8, 2024, 02:56

Tejas Patil: First patient with mNSCLC with an EGFR-ERBB4 gene fusion who clinically and radiographically responded to EGFR TKIs

Tejas Patil, Thoracic oncologist at University of Colorado Cancer Center, shared a post on X:

“Along with my CU Cancer Center colleagues, I’m very proud to present the FIRST case of a patient with metastatic NSCLC with an EGFR-ERBB4 gene fusion who clinically and radiographically responded to sequential EGFR TKIs, now published in JCO Precision Oncology.

Tejas Patil

Key points:

Point 1: ERBB4 fusions represent 0.1% of all ERBB fusions. In a prior study, EGFR::ERBB4 cancer cells treated with EGFR TKIs including osimertinib and tarloxotinib, had decreased levels of activated EGFR, ERBB4, and downstream signaling proteins.

Tejas Patil

Point 2: RNA-based fusion testing in our pt revealed an in-frame transcript between EGFR exon 25 and ERBB4 exon 18. Shows importance of RNA NGS for gene fusions in NSCLC! This fusion product is anticipated to juxtapose the TKDs while conserving ERBB4 protein interaction motifs.

Tejas Patil: First patient with mNSCLC with an EGFR-ERBB4 gene fusion who clinically and radiographically responded to EGFR TKIs

Point 3: Pt was HEAVILY pre-treated with complex course. Received mobocertinib (compassionate access) because of insurance coverage issues. Had CNS progression on mobo, which prompted switch to osimertinib. Remains on therapy with excellent treatment response to this day.

Tejas Patil: First patient with mNSCLC with an EGFR-ERBB4 gene fusion who clinically and radiographically responded to EGFR TKIs

Clinical and Radiographic Benefit of a Patient With Metastatic Non-Small Cell Lung Cancer Harboring an EGFR::ERBB4 Fusion Through Use of EGFR Tyrosine Kinase Inhibitors

Authors: Amy Guimaraes-Young, Kurtis D. Davies, Patricia Trevisan, Hala Nijmeh, Mary Haag, Dara L. Aisner, and Tejas Patil

Tejas Patil: First patient with mNSCLC with an EGFR-ERBB4 gene fusion who clinically and radiographically responded to EGFR TKIs

Amy Guimaraes-Young and Tejas Patil cancer Dara L. Aisner Hala Nijmeh JCO Precision Oncology Kurtis D. Davies Mary Haag NSCLC OncoDaily Oncology Patricia Trevisan Tejas Patil

Highlights from Global Cancer Movement: Challenging the Status Quo in Colorectal Cancer - Day 1

100 Influential Women in Oncology: Key Opinion Leaders to follow on Social Media in 2024

Have faith in yourself, and look out for the bad man - reflections from Neil Ranasinghe's involvement in LGCW

Top 100 Xfluencers in Lung Cancer: Key Opinion Leaders to Follow on X (Twitter) in 2024

Eric Bouffet: New hope for children and adults with hemianopia

Special Coverage